Clinical trial
Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B…
NCT00305019 · Bukwang Pharmaceutical, Industry · Terminated
Key facts
| NCT number | NCT00305019 |
|---|---|
| Title | Safety and Antiviral Activity of Clevudine in Patients Infected With Hepatitis B Virus |
| Official title | A Double- Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 Mg QD and 50 Mg QD Doses in Patients Infected With Hepatitis B Virus |
| Lead sponsor | Bukwang Pharmaceutical, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | clevudine |
| Enrollment | 120 |
| Start date | Jul 1, 2002 |
| Completion | Mar 1, 2004 |
| First posted | Mar 21, 2006 |
| Last update posted | Apr 12, 2006 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: